Skip to main content
Evidence Snapshot

P388

CHEMBL389 CELL-LINE Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T01:49:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL389
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats P388 as ChEMBL target CHEMBL389. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
P388
CELL-LINE · Mus musculus
As of 2026-09-14
ChEMBL target ID
CHEMBL389
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why P388 matters

As of 2026-09-14

P388 is reviewed as P388; the current evidence base includes 31 approved drugs, 9798 compounds, and 4875 assays, with lead potency reaching pChEMBL 10.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 31 approved drugs, 9798 compounds, and 4875 assays for this target. The dominant activity type is IC50. CHEMBL256099 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL256099 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
31 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why P388 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9798
Total Compounds
4875
Total Assays
31
Approved Drugs
IC50: 4452.0, KI: 2.0, EC50: 69.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL256099
10.9 IC50
No preferred name
CHEMBL274951
10.7 IC50
No preferred name
CHEMBL255716
10.7 IC50
No preferred name
CHEMBL256302
10.5 IC50
No preferred name
CHEMBL1797231
10.5 IC50

Approved Drugs

Structure Compound First Approval
PLITIDEPSIN
CHEMBL451930
2018
TOPOTECAN
CHEMBL84
1996
DOCETAXEL
CHEMBL3545252
1995
TRIMETREXATE
CHEMBL119
1993
PACLITAXEL
CHEMBL428647
1992
PODOFILOX
CHEMBL61
1990
1987
AMSACRINE
CHEMBL43
1987
ETOPOSIDE
CHEMBL44657
1983
MITOMYCIN
CHEMBL105
1981
1979
DAUNORUBICIN
CHEMBL178
1979
DOXORUBICIN
CHEMBL53463
1974
1974
PLICAMYCIN
CHEMBL1237054
1970
CYTARABINE
CHEMBL803
1969
THIOGUANINE
CHEMBL727
1966
VINBLASTINE
CHEMBL159
1965
DACTINOMYCIN
CHEMBL1554
1964
MELPHALAN
CHEMBL852
1964
VINCRISTINE
CHEMBL90555
1963
FLUOROURACIL
CHEMBL185
1962
COLCHICINE
CHEMBL107
1961
METHOTREXATE
CHEMBL34259
1953
EMETINE
CHEMBL50588
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T01:49:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL389